Published in Cancer Weekly, July 28th, 1997
Cell Therapeutics, Inc., Seattle, Washington, announced preliminary results from a Phase II trial of its lead drug candidate, lisofylline (LSF), among patients with newly diagnosed acute myeloid leukemia.
The randomized, double-blind, placebo-controlled trial of the Cell Therapeutic Inc. (Seattle, Washington) product was conducted at the University of Texas M.D. Anderson Cancer Center, Houston, Texas, under direction of principal investigator Elihu Estey, M.D.
In this trial, 70 patients, ages 19 to 70 years,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.